Evogene grants Adrian John Percy 2,500 stock options

The stated $0.58 exercise price is equivalent to NIS 1.75 at the September 4, 2026 representative rate of NIS 3.0050 per U.S. dollar.

Rhea-AI Filing Summary

Evogene Ltd. (EVGN) director Adrian John Percy received a grant of 2,500 stock options on September 4, 2026, under the 2021 Share Incentive Plan. The options have a $0.58-per-share exercise price and vest 25% per quarter beginning on the grant date, becoming fully vested by September 4, 2027; they expire September 4, 2036. Separately, reported direct options include 1,000 underlying shares at $25.60, expiring December 23, 2028, and 2,500 at $1.29, expiring August 18, 2035.

Insider Trade Summary

Grant/Award: 2,500 shares

Grant/Award 9 txns

Insider Percy Adrian John

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1, F2, F3	2,500	$0.00	$0.00
holding	Stock Option (right to buy) F4	--	--	--
holding	Stock Option (right to buy) F4	--	--	--
holding	Stock Option (right to buy) F4	--	--	--
holding	Stock Option (right to buy) F4	--	--	--
holding	Stock Option (right to buy) F4	--	--	--
holding	Stock Option (right to buy) F4	--	--	--
holding	Stock Option (right to buy) F4	--	--	--
holding	Stock Option (right to buy) F4	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 13,700 contracts for 11,200 underlying shares (Direct)

Footnotes (4)

1. F1. The exercise price of the stock options to purchase Ordinary Shares of the Issuer (the "Options") is New Israeli Shekels ("NIS") 1.75 per share, which is equivalent to $0.58 per share based on the representative exchange rate of NIS 3.0050 per U.S. dollar published by the Bank of Israel on September 4, 2026, the grant date.
2. F2. The transaction reported in this row consists of the grant by the Issuer's board of directors to the Reporting Person of 2,500 Options under the Issuer's 2021 Share Incentive Plan.
3. F3. The Options vest and become exercisable on a quarterly basis (25% per quarter) commencing on the grant date of September 4, 2026, such that they will be fully vested by September 4, 2027, the one-year anniversary of the grant date.
4. F4. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.

Key Figures

Options granted: 2,500 options Exercise price: $0.58 per share Exercise price: NIS 1.75 per share +3 more

6 metrics

Options granted 2,500 options September 4, 2026 grant

Exercise price $0.58 per share Options granted on September 4, 2026

Exercise price NIS 1.75 per share Equivalent to $0.58 per share

Quarterly vesting 25% per quarter Vesting begins on the grant date

Fully vested by September 4, 2027 One-year anniversary of the grant date

Option expiration September 4, 2036 Options granted on September 4, 2026

Key Terms

2021 Share Incentive Plan, exercise price, vest and become exercisable, representative exchange rate

4 terms

2021 Share Incentive Plan financial

"under the Issuer's 2021 Share Incentive Plan"

exercise price financial

"The exercise price of the stock options"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable technical

"The Options vest and become exercisable on a quarterly basis"

representative exchange rate financial

"based on the representative exchange rate"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did EVGN director Adrian John Percy receive?

Adrian John Percy received 2,500 stock options on September 4, 2026, under Evogene's 2021 Share Incentive Plan. The options have an exercise price of $0.58 per share.

How was the $0.58 EVGN option exercise price calculated?

The stated exercise price is NIS 1.75 per share, equivalent to $0.58 per share using the representative rate of NIS 3.0050 per U.S. dollar published by the Bank of Israel on September 4, 2026, the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/30/2026 - 08:07 AM Accepted by SEC EDGAR 09/30/2026 - 08:07 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Percy Adrian John

(Last) (First) (Middle)

840 OVAL DRIVE

(Street)

RALEIGH NORTH CAROLINA 27606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Evogene Ltd. [ EVGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.58(1)	09/04/2026		A(2)		2,500		(3)	09/04/2036	Ordinary Shares	2,500	$0	2,500	D
Stock Option (right to buy)(4)	$25.6							12/23/2019	12/23/2028	Ordinary Shares	1,000		1,000	D
Stock Option (right to buy)(4)	$4.89							02/01/2021	02/01/2030	Ordinary Shares	250		250	D
Stock Option (right to buy)(4)	$62.68							02/01/2022	02/01/2031	Ordinary Shares	250		250	D
Stock Option (right to buy)(4)	$29.8							08/10/2022	08/10/2031	Ordinary Shares	1,800		1,800	D
Stock Option (right to buy)(4)	$10.2							09/15/2023	09/15/2032	Ordinary Shares	1,800		1,800	D
Stock Option (right to buy)(4)	$6.4							05/11/2024	05/11/2033	Ordinary Shares	1,800		1,800	D
Stock Option (right to buy)(4)	$6.6							06/13/2025	06/13/2034	Ordinary Shares	1,800		1,800	D
Stock Option (right to buy)(4)	$1.29							08/18/2026	08/18/2035	Ordinary Shares	2,500		2,500	D

Explanation of Responses:

1. The exercise price of the stock options to purchase Ordinary Shares of the Issuer (the "Options") is New Israeli Shekels ("NIS") 1.75 per share, which is equivalent to $0.58 per share based on the representative exchange rate of NIS 3.0050 per U.S. dollar published by the Bank of Israel on September 4, 2026, the grant date.

2. The transaction reported in this row consists of the grant by the Issuer's board of directors to the Reporting Person of 2,500 Options under the Issuer's 2021 Share Incentive Plan.

3. The Options vest and become exercisable on a quarterly basis (25% per quarter) commencing on the grant date of September 4, 2026, such that they will be fully vested by September 4, 2027, the one-year anniversary of the grant date.

4. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.

Remarks:

Exhibit 24.1 - Power of Attorney.

	/s/ Nitsan Deutsch, attorney-in-fact	09/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)